Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1344 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-14

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted in Europe. The intention of this health service research study is to obtain data from daily routine to evaluate the quality of life and the costs of the disease for patients with type 2 diabetes mellitus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00154401

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE2

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

NCT01319240

Diabetes Healthy

COMPLETED PHASE1

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

NCT01288326

Diabetes Diabetes Mellitus, Type 2

COMPLETED

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00318422

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE3

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

NCT01973231

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide

liraglutide

Intervention Type DRUG

Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.

Any insulin

insulin

Intervention Type DRUG

Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

liraglutide

Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.

Intervention Type DRUG

insulin

Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent obtained before any study-related activities. (Study-related activities are any procedures related to recording of data according to the protocol)
* Patients willing and able to give signed consent on matching patient data with sick fund data
* Patients diagnosed with type 2 diabetes mellitus, currently treated with oral antidiabetic medication, who need treatment intensification with insulin or liraglutide (Victoza®) due to inadequate blood glucose control
* Patient is a member of the involved sick fund (AOK Plus)

Exclusion Criteria

* Known or suspected contra-indication to the relevant study product according to current SPC
* Previous participation in this study
* History of type 1 diabetes mellitus
* Previous insulin treatment excluding emergency administration (treatment duration up to a maximum of 3 days)
* Previous treatment with liraglutide
* History of diabetic gastroparesis, diabetic precoma or diabetic ketoacidosis
* Progressive fatal disease
* Any reason in judgement of the treating physician that precludes study participation e.g. lack of compliance, safety concerns, alcohol or drug abuse
* Patients without legal capacity

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No